April 22 (Reuters) - The U.S. FDA had approved ImmunityBio's combination therapy to treat a type of bladder cancer, the company said on Monday.
(Reporting by Puyaan Singh; Editing by Sherry Jacob-Phillips)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.96 USD | -4.49% | -3.09% | +18.73% |
April 22 (Reuters) - The U.S. FDA had approved ImmunityBio's combination therapy to treat a type of bladder cancer, the company said on Monday.
(Reporting by Puyaan Singh; Editing by Sherry Jacob-Phillips)
1st Jan change | Capi. | |
---|---|---|
+18.73% | 4.32B | |
+18.34% | 125B | |
+15.06% | 108B | |
-6.39% | 23.64B | |
+2.39% | 22.39B | |
-12.11% | 17.78B | |
-41.64% | 16.43B | |
-12.07% | 16.34B | |
+1.05% | 13.56B | |
+25.87% | 11.59B |